Biohaven Pharmaceutical Company (BHVN) Stock Forecast, Price Target & Predictions
BHVN Stock Forecast
Biohaven Pharmaceutical Company stock forecast is as follows: an average price target of $56.40 (represents a 21.81% upside from BHVN’s last price of $46.30) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.
BHVN Price Target
The average price target for Biohaven Pharmaceutical Company (BHVN) is $56.40 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $68.00 to $23.00. This represents a potential 21.81% upside from BHVN's last price of $46.30.
BHVN Analyst Ratings
According to 12 Wall Street analysts, Biohaven Pharmaceutical Company's rating consensus is 'Buy'. The analyst rating breakdown for BHVN stock is 0 'Strong Buy' (0.00%), 12 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Biohaven Pharmaceutical Company Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 15, 2024 | Jason Gerberry | Bank of America Securities | $65.00 | $52.77 | 23.18% | 40.39% |
| Sep 24, 2024 | Marc Goodman | Leerink Partners | $60.00 | $44.22 | 35.69% | 29.59% |
| Sep 24, 2024 | Douglas Tsao | H.C. Wainwright | $59.00 | $45.94 | 28.43% | 27.43% |
| Sep 24, 2024 | Jason Gerberry | Bank of America Securities | $62.00 | $45.94 | 34.96% | 33.91% |
| Sep 24, 2024 | Leonid Timashev | RBC Capital | $68.00 | $45.94 | 48.02% | 46.87% |
| Sep 23, 2024 | Brian Skorney | Robert W. Baird | $60.00 | $46.56 | 28.87% | 29.59% |
| Sep 23, 2024 | Thomas Shrader | BTIG | $59.00 | $46.56 | 26.72% | 27.43% |
| Sep 16, 2024 | Amy Li | Jefferies | $57.00 | $38.08 | 49.68% | 23.11% |
| Sep 04, 2024 | William Pickering | Tudor Pickering | $55.00 | $38.17 | 44.09% | 18.79% |
| Jul 24, 2024 | Terence Flynn | Morgan Stanley | $58.00 | $37.81 | 53.40% | 25.27% |
The latest Biohaven Pharmaceutical Company stock forecast, released on Oct 15, 2024 by Jason Gerberry from Bank of America Securities, set a price target of $65.00, which represents a 23.18% increase from the stock price at the time of the forecast ($52.77), and a 40.39% increase from BHVN last price ($46.30).
Biohaven Pharmaceutical Company Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 9 | 12 |
| Avg Price Target | - | $60.56 | $60.00 |
| Last Closing Price | $46.30 | $46.30 | $46.30 |
| Upside/Downside | -100.00% | 30.80% | 29.59% |
In the current month, the average price target of Biohaven Pharmaceutical Company stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Biohaven Pharmaceutical Company's last price of $46.30. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 15, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Sep 24, 2024 | Leerink Partners | Outperform | Outperform | Hold |
| Sep 24, 2024 | Bernstein | Outperform | Outperform | Hold |
| Sep 24, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 24, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Sep 24, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Sep 23, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 23, 2024 | BTIG | Buy | Buy | Hold |
| Sep 16, 2024 | Jefferies | - | Buy | Initialise |
Biohaven Pharmaceutical Company's last stock rating was published by Bank of America Securities on Oct 15, 2024. The company gave BHVN a "Buy" rating, the same as its previous rate.
Biohaven Pharmaceutical Company Financial Forecast
Biohaven Pharmaceutical Company Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $-215.08M | - | - | - |
| Avg Forecast | $31.61M | $27.68M | $23.49M | $19.58M | $5.57M | $2.71M | $2.50M | $2.50M | $11.11M | $1.67K | - | $318.71M | $289.74M | $204.23M | $263.40M | $36.41M | $877.31K |
| High Forecast | $31.61M | $27.68M | $23.49M | $19.58M | $5.57M | $2.71M | $2.50M | $2.50M | $11.11M | $1.67K | - | $382.46M | $347.69M | $245.07M | $316.08M | $43.69M | $1.05M |
| Low Forecast | $31.61M | $27.68M | $23.49M | $19.58M | $5.57M | $2.71M | $2.50M | $2.50M | $11.11M | $1.67K | - | $254.97M | $231.79M | $163.38M | $210.72M | $29.13M | $701.85K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 4 | - | 14 | 19 | 12 | 14 | 17 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.05% | - | - | - |
Biohaven Pharmaceutical Company's average Quarter revenue forecast for Mar 23 based on 19 analysts is $289.74M, with a low forecast of $231.79M, and a high forecast of $347.69M. BHVN's average Quarter revenue forecast represents a -234.71% decrease compared to the company's last Quarter revenue of $-215.08M (Dec 22).
Biohaven Pharmaceutical Company EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 4 | - | 14 | 19 | 12 | 14 | 17 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-76.13M | $-213.07M | $-89.52M | - | - |
| Avg Forecast | $22.31M | $19.54M | $16.58M | $13.82M | $3.93M | $1.91M | $1.76M | $1.76M | $7.84M | $1.18K | - | $-45.23M | $-41.12M | $-95.15M | $-37.38M | $-126.57M | $-108.89M |
| High Forecast | $22.31M | $19.54M | $16.58M | $13.82M | $3.93M | $1.91M | $1.76M | $1.76M | $7.84M | $1.18K | - | $-36.18M | $-32.89M | $-76.12M | $-29.90M | $-101.26M | $-87.11M |
| Low Forecast | $22.31M | $19.54M | $16.58M | $13.82M | $3.93M | $1.91M | $1.76M | $1.76M | $7.84M | $1.18K | - | $-54.27M | $-49.34M | $-114.18M | $-44.85M | $-151.88M | $-130.66M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.85% | 2.24% | 2.40% | - | - |
undefined analysts predict BHVN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Biohaven Pharmaceutical Company's previous annual EBITDA (undefined) of $NaN.
Biohaven Pharmaceutical Company Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 4 | - | 14 | 19 | 12 | 14 | 17 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-70.49M | $-201.11M | $-97.03M | - | - |
| Avg Forecast | $-138.39M | $-140.26M | $-142.48M | $-149.11M | $-158.83M | $-156.06M | $-157.49M | $-160.12M | $-151.69M | $-160.58M | $-156.29M | $-116.35M | $-105.77M | $-126.41M | $-96.16M | $-147.80M | $-118.99M |
| High Forecast | $-138.39M | $-140.26M | $-142.48M | $-149.11M | $-158.83M | $-156.06M | $-157.49M | $-132.58M | $-42.78M | $-160.58M | $-156.29M | $-93.08M | $-84.62M | $-101.13M | $-76.92M | $-118.24M | $-95.19M |
| Low Forecast | $-138.39M | $-140.26M | $-142.48M | $-149.11M | $-158.83M | $-156.06M | $-157.49M | $-202.95M | $-209.06M | $-160.58M | $-156.29M | $-139.62M | $-126.93M | $-151.70M | $-115.39M | $-177.36M | $-142.78M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.67% | 1.59% | 1.01% | - | - |
Biohaven Pharmaceutical Company's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BHVN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Biohaven Pharmaceutical Company SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 4 | - | 14 | 19 | 12 | 14 | 17 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $14.32M | $76.37M | $19.68M | - | - |
| Avg Forecast | $25.80M | $22.59M | $19.17M | $15.98M | $4.55M | $2.21M | $2.04M | $2.04M | $9.07M | $1.36K | - | $227.14M | $206.49M | $139.28M | $187.72M | $29.72M | $716.04K |
| High Forecast | $25.80M | $22.59M | $19.17M | $15.98M | $4.55M | $2.21M | $2.04M | $2.04M | $9.07M | $1.36K | - | $272.57M | $247.79M | $167.14M | $225.27M | $35.66M | $859.25K |
| Low Forecast | $25.80M | $22.59M | $19.17M | $15.98M | $4.55M | $2.21M | $2.04M | $2.04M | $9.07M | $1.36K | - | $181.72M | $165.20M | $111.42M | $150.18M | $23.77M | $572.83K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.07% | 0.55% | 0.10% | - | - |
Biohaven Pharmaceutical Company's average Quarter SG&A projection for Mar 24 is $227.14M, based on 14 Wall Street analysts, with a range of $181.72M to $272.57M. The forecast indicates a 1486.09% rise compared to BHVN last annual SG&A of $14.32M (Mar 23).
Biohaven Pharmaceutical Company EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 4 | - | 14 | 19 | 12 | 14 | 17 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-1.03 | $-3.32 | $-2.71 | - | - |
| Avg Forecast | $-1.47 | $-1.49 | $-1.51 | $-1.58 | $-1.68 | $-1.65 | $-1.67 | $-1.70 | $-1.61 | $-1.70 | $-1.78 | $-1.55 | $-1.41 | $-1.22 | $1.43 | $-1.57 | $-1.61 |
| High Forecast | $-1.47 | $-1.49 | $-1.51 | $-1.58 | $-1.68 | $-1.65 | $-1.67 | $-1.40 | $-0.45 | $-1.70 | $-1.78 | $-1.55 | $-1.41 | $-1.22 | $1.43 | $-1.26 | $-1.29 |
| Low Forecast | $-1.47 | $-1.49 | $-1.51 | $-1.58 | $-1.68 | $-1.65 | $-1.67 | $-2.15 | $-2.22 | $-1.70 | $-1.78 | $-1.55 | $-1.41 | $-1.22 | $1.43 | $-1.89 | $-1.93 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | 2.72% | -1.90% | - | - |
According to undefined Wall Street analysts, Biohaven Pharmaceutical Company's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BHVN previous annual EPS of $NaN (undefined).
Biohaven Pharmaceutical Company Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
| INZY | Inozyme Pharma | $2.81 | $14.67 | 422.06% | Buy |
| CCCC | C4 Therapeutics | $4.15 | $13.50 | 225.30% | Buy |
| IMNM | Immunome | $9.39 | $30.33 | 223.00% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.52 | $38.80 | 186.98% | Buy |
| APLS | Apellis Pharmaceuticals | $28.99 | $74.50 | 156.99% | Buy |
| TERN | Terns Pharmaceuticals | $5.91 | $14.25 | 141.12% | Buy |
| MREO | Mereo BioPharma Group | $3.49 | $6.75 | 93.41% | Buy |
| NRIX | Nurix Therapeutics | $22.79 | $32.20 | 41.29% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.22 | $6.67 | 27.78% | Buy |
| BHVN | Biohaven Pharmaceutical Company | $46.30 | $56.40 | 21.81% | Buy |
| KYMR | Kymera Therapeutics | $42.84 | $51.50 | 20.21% | Buy |
| BPMC | Blueprint Medicines | $94.60 | $109.71 | 15.97% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $56.47 | $60.63 | 7.37% | Buy |
| AGIO | Agios Pharmaceuticals | $54.41 | $48.00 | -11.78% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |